Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study
- Registration Number
- NCT03512860
- Lead Sponsor
- Estetra
- Brief Summary
The present study is designed to determine the effect of valproic acid (VAL), a UGT2B7 inhibiting drug, on the pharmacokinetics (PK) of estetrol (E4)
- Detailed Description
In the present study, E4/DRSP will be administered alone (Treatment A) and in combination with VAL (Treatment B) following two sequences A-B or B-A.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
- Healthy premenopausal, aged 18-45 years (inclusive) at the time of signing informed consent.
- For subjects who are sexually active and are of childbearing potential: willing to use a highly effective non-hormonal method of contraception from screening until the follow-up assessment, such as (but not limited to): non-hormonal intra-uterine device (copper IUD), bilateral tubal occlusion, vasectomised partner, or sexual abstinence in a heterosexual relationship; this is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, they, with their partner, must comply with the contraceptive requirements as stated earlier.
- Body weight ≥45 kg, and a body mass index between 18.0 and 30.0 kg/m² (inclusive).
- Negative serum pregnancy test at screening and a negative urine pregnancy test at Day -1.
Exclusion Criteria
-
The use of:
- any prescription drugs, including oral or vaginal hormonal contraceptives, from 28 days prior to first dose administration until study completion;
- any herbal medication or dietary supplements acting on cytochrome P450 3A4 (CYP3A4) functions (i.e., St John's Wort), from 28 days prior to first dose administration until study completion;
- any over-the-counter medication (including paracetamol or dietary supplements (including vitamins and herbal products ), from 14 days prior to first dose administration until study completion. Limited use (i.e., up to 1200 mg/day) of ibuprofen is allowed;
- any depot progestogen preparations or an injectable hormonal method of contraception, from 6 months prior to the first dose administration until study completion.
-
History of hypersensitivity, serious adverse reaction, or existing contraindication to E4, DRSP or VAL, or excipients.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B) E4/DRSP Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration. E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A) E4/DRSP Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP). E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B) VAL Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration. E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A) VAL Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
- Primary Outcome Measures
Name Time Method Maximum concentration (Cmax) of E4 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
Area under the plasma concentration versus time curve from time 0 to the last determined concentration (AUC0-tdlc) of E4 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
Area under the plasma concentration versus time curve from time 0 to infiny (AUC0-inf) of E4 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
- Secondary Outcome Measures
Name Time Method Number of subjects with adverse events as a measure of safety and tolerability The total study duration (between 50 and 86 days) Cmax of DRSP 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
Cmax of E4-glucuronide metabolites 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
AUC0-tdlc of DRSP 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
AUC0-tdlc of E4-glucuronide metabolites 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
AUC0-inf of DRSP 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
AUC0-inf of E4-glucuronide metabolites 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A PK sampling
Trial Locations
- Locations (1)
Quotient Sciences
🇬🇧Ruddington, Nottingham, United Kingdom